Von Willebrand factor-rich platelet thrombi in the liver cause sinusoidal obstruction syndrome following oxaliplatin-based chemotherapy

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Nishigori, Naoto ^a   Matsumoto, Masanori ^a   Koyama, Fumikazu ^a   Hayakawa, Masaki ^a   Hatakeyayama, Kinta ^a   Ko, Saiho ^a   Fujimura, Yoshihiro ^a   Nakajima, Yoshiyuki ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; BILIRUBIN; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; OXALIPLATIN; PANITUMUMAB; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR ANTIBODY; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ANGIOGENESIS INHIBITOR; AUTOANTIBODY; FIBRINOGEN RECEPTOR; PLATINUM COMPLEX;

ADJUVANT CHEMOTHERAPY; ADULT; ADVERSE DRUG REACTION; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD CLOTTING; BLOOD EXAMINATION; CANCER COMBINATION CHEMOTHERAPY; CARCINOGENESIS; CHEMOTHERAPY ASSOCIATED LIVER INJURY; CLINICAL ARTICLE; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER; LIVER INJURY; LIVER PROTECTION; LIVER VENOOCCLUSIVE DISEASE; MALE; METASTASIS POTENTIAL; MICROTHROMBUS; MIDDLE AGED; MOLECULAR WEIGHT; PATHOGENESIS; PLATELET THROMBUS FORMATION; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; SIDE EFFECT; SPLEEN SIZE; SPLENOMEGALY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; BLOOD; CANCER STAGING; COLORECTAL NEOPLASMS; DISEASE COURSE; DRUG EFFECTS; HEPATIC VENO-OCCLUSIVE DISEASE; METABOLISM; PATHOLOGY; THROMBOCYTE; THROMBOSIS;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ASPARTATE AMINOTRANSFERASES; AUTOANTIBODIES; BEVACIZUMAB; BLOOD PLATELETS; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; ENDOTHELIAL CELLS; FEMALE; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; SPLENOMEGALY; THROMBOSIS; VON WILLEBRAND FACTOR;

EID: 84958036456     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0143136     Document Type: Article

References (34)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA: a cancer journal for clinicians. 2012; 62 (1):10-29. doi: 10.3322/caac.20138 PMID: 22237781.
2. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2000; 18(16):2938-47. PMID: 10944126.
3. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2004; 22(2):229-37. doi: 10.1200/JCO.2004.05.113 PMID: 14657227.
4. Robinson S, Manas DM, Pedley I, Mann D, White SA. Systemic chemotherapy and its implications for resection of colorectal liver metastasis. Surgical oncology. 2011; 20(2):57-72. doi: 10.1016/j.suronc. 2009.10.002 PMID: 19962301.
5. Schwarz RE, Berlin JD, Lenz HJ, Nordlinger B, Rubbia-Brandt L, Choti MA. Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement. HPB: the official journal of the International Hepato Pancreato Biliary Association. 2013; 15(2):106-15. doi: 10.1111/j.1477-2574. 2012.00558.x PMID: 23297721; PubMed Central PMCID: PMC3719916.
6. Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Annals of oncology: official journal of the European Society for Medical Oncology /ESMO. 2004; 15(3):460-6. PMID: 14998849.
7. Overman MJ, Maru DM, Charnsangavej C, Loyer EM, Wang H, Pathak P, et al. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010; 28(15):2549-55. doi: 10.1200/JCO.2009.27.5701 PMID: 20406923.
8. Jung EJ, Ryu CG, Kim G, Kim SR, Park HS, Kim YJ, et al. Splenomegaly during oxaliplatin-based chemotherapy for colorectal carcinoma. Anticancer research. 2012; 32(8):3357-62. PMID: 22843915.
9. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. The New England journal of medicine. 2004; 350(23):2335-42. doi: 10.1056/NEJMoa032691 PMID: 15175435.
10. Kishi Y, Zorzi D, Contreras CM, Maru DM, Kopetz S, Ribero D, et al. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Annals of surgical oncology. 2010; 17(11):2870-6. doi: 10. 1245/s10434-010-1166-1 PMID: 20567921.
11. Ribero D, Wang H, Donadon M, Zorzi D, Thomas MB, Eng C, et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer. 2007; 110(12):2761-7. doi: 10.1002/cncr.23099 PMID: 17960603.
12. Park YD, Yoshioka A, Kawa K, Ishizashi H, Yagi H, Yamamoto Y, et al. Impaired activity of plasma von Willebrand factor-cleaving protease may predict the occurrence of hepatic veno-occlusive disease after stem cell transplantation. Bone marrow transplantation. 2002; 29(9):789-94. doi: 10.1038/sj.bmt. 1703544 PMID: 12040478.
13. Matsumoto M, Kawa K, Uemura M, Kato S, Ishizashi H, Isonishi A, et al. Prophylactic fresh frozen plasma may prevent development of hepatic VOD after stem cell transplantation via ADAMTS13-mediated restoration of von Willebrand factor plasma levels. Bone marrow transplantation. 2007; 40(3):251-9. doi: 10.1038/sj.bmt.1705724 PMID: 17549054.
14. Moake JL. Thrombotic microangiopathies. The New England journal of medicine. 2002; 347(8):589-600. doi: 10.1056/NEJMra020528 PMID: 12192020.
15. Dong JF, Moake JL, Nolasco L, Bernardo A, Arceneaux W, Shrimpton CN, et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood. 2002; 100(12):4033-9. doi: 10.1182/blood-2002-05-1401 PMID: 12393397.
16. Matsumoto M, Kawaguchi S, Ishizashi H, Yagi H, Iida J, Sakaki T, et al. Platelets treated with ticlopidine are less reactive to unusually large von Willebrand factor multimers than are those treated with aspirin under high shear stress. Pathophysiology of haemostasis and thrombosis. 2005; 34(1):35-40. Epub 2005/11/19. doi: 10.1159/000088546 PMID: 16293984.
17. Kato S, Matsumoto M, Matsuyama T, Isonishi A, Hiura H, Fujimura Y. Novel monoclonal antibodybased enzyme immunoassay for determining plasma levels of ADAMTS13 activity. Transfusion. 2006; 46(8):1444-52. Epub 2006/08/29. TRF00914 [pii] doi: 10.1111/j.1537-2995.2006.00914.x PMID: 16934083.
18. Ruggeri ZM, Zimmerman TS. Variant von Willebrand's disease: characterization of two subtypes by analysis of multimeric composition of factor VIII/von Willebrand factor in plasma and platelets. The Journal of clinical investigation. 1980; 65(6):1318-25. Epub 1980/06/01. doi: 10.1172/JCI109795 PMID: 6773982; PubMed Central PMCID: PMC371469.
19. Warren CM, Krzesinski PR, Greaser ML. Vertical agarose gel electrophoresis and electroblotting of high-molecular-weight proteins. Electrophoresis. 2003; 24(11):1695-702. doi: 10.1002/elps. 200305392 PMID: 12783444.
20. Budde U, Schneppenheim R, Plendl H, Dent J, Ruggeri ZM, Zimmerman TS. Luminographic detection of von Willebrand factor multimers in agarose gels and on nitrocellulose membranes. Thrombosis and haemostasis. 1990; 63(2):312-5. Epub 1990/04/12. PMID: 2363131.
21. Budde U, Drewke E, Mainusch K, Schneppenheim R. Laboratory diagnosis of congenital von Willebrand disease. Semin Thromb Hemost. 2002; 28(2):173-90. doi: 10.1055/s-2002-27820 PMID: 11992241.
22. Klinger M, Eipeldauer S, Hacker S, Herberger B, Tamandl D, Dorfmeister M, et al. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol. 2009; 35(5):515-20. doi: 10.1016/j.ejso.2008.12.013 PMID: 19200687.
23. Rubbia-Brandt L, Lauwers GY, Wang H, Majno PE, Tanabe K, Zhu AX, et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology. 2010; 56(4):430-9. doi: 10.1111/j.1365-2559.2010.03511.x PMID: 20459550.
24. Furlan M. Von Willebrand factor: molecular size and functional activity. Ann Hematol. 1996; 72(6):341-8. PMID: 8767102.
25. Perez-Rodriguez A, Pinto JC, Loures E, Rodriguez-Trillo A, Cuenca JJ, Batlle J, et al. Acquired von Willebrand syndrome and mitral valve prosthesis leakage. A pilot study. Eur J Haematol. 2011; 87 (5):448-56. doi: 10.1111/j.1600-0609.2011.01664.x PMID: 21668503.
26. McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology. 1984; 4 (1):116-22. PMID: 6363247.
27. DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis. 2002; 22(1):27-42. doi: 10.1055/s-2002-23204 PMID: 11928077.
28. Lenting PJ, Christophe OD, Denis CV. von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends. Blood. 2015; 125(13):2019-28. doi: 10.1182/blood-2014-06-528406 PMID: 25712991.
29. Rondaij MG, Bierings R, Kragt A, van Mourik JA, Voorberg J. Dynamics and plasticity of Weibel-Palade bodies in endothelial cells. Arterioscler Thromb Vasc Biol. 2006; 26(5):1002-7. doi: 10.1161/01.ATV. 0000209501.56852.6c PMID: 16469951.
30. Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. 1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases. Lancet. 1977; 1(8017):869-72. PMID: 67283.
31. Uemura M, Tatsumi K, Matsumoto M, Fujimoto M, Matsuyama T, Ishikawa M, et al. Localization of ADAMTS13 to the stellate cells of human liver. Blood. 2005; 106(3):922-4. doi: 10.1182/blood-2005-01-0152 PMID: 15855280.
32. Matsushita K, Yamakuchi M, Morrell CN, Ozaki M, O'Rourke B, Irani K, et al. Vascular endothelial growth factor regulation of Weibel-Palade-body exocytosis. Blood. 2005; 105(1):207-14. doi: 10.1182/blood-2004-04-1519 PMID: 15345585; PubMed Central PMCID: PMC2705620.
33. Bauer AT, Suckau J, Frank K, Desch A, Goertz L, Wagner AH, et al. von Willebrand factor fibers promote cancer-associated platelet aggregation in malignant melanoma of mice and humans. Blood. 2015; 125(20):3153-63. doi: 10.1182/blood-2014-08-595686 PMID: 25977583; PubMed Central PMCID: PMCPMC4432010.
34. Iguchi A, Kobayashi R, Yoshida M, Kobayashi K, Matsuo K, Kitajima I, et al. Vascular endothelial growth factor (VEGF) is one of the cytokines causative and predictive of hepatic veno-occlusive disease (VOD) in stem cell transplantation. Bone marrow transplantation. 2001; 27(11):1173-80. doi: 10. 1038/sj.bmt.1703061 PMID: 11551028.